Literature DB >> 20490961

Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.

Emanuela Anastasi1, Teresa Granato, Giulia Giovanna Marchei, Valentina Viggiani, Barbara Colaprisca, Sara Comploj, Maria Gabriella Reale, Luigi Frati, Cecilia Midulla.   

Abstract

The objective of the present study was to investigate in healthy young women the fluctuations in serum concentration of human epididymal secretory protein human epididymis-specific protein 4 (HE4) and CA125 during the phases of the menstrual cycle and the correlation between HE4 and CA125 values and age. Forty women with regular menstrual cycles were included in the study. Pelvic and transvaginal ultrasound were performed in order to exclude ovarian pathologies. Blood samples were collected at follicular (FP), ovulatory (OP), and luteal (LP) phases of the hormonal cycle. The values of HE4 (expressed as picomoles per liter) observed were (mean ± SEM) 39.1 ± 1.1 (FP), 45.3 ± 1.19 (OP), and 42.0 ± 1.3 (LP). The difference between FP and OP was statistically significant (p = 0.0002). By contrast, serum CA125 levels (expressed as units per milliliter) were 14.35 ± 0.66 (FP), 13.15 ± 0.54 (OP), and 13.70 ± 0.54 (LP), respectively. The levels of HE4 observed in serum samples of women below 35 years were 37.5 ± 1.28 in the FP, 46.6 ± 1.4 in the OP, and 42.8 ± 1.49 in the LP. In this group, a statistically significant difference was observed in the FP compared with the OP (p < 0.0001), whereas no statistically significant difference was observed during the different hormonal phases in the group of women over 35. In conclusion, the correct interpretation of laboratory data is essential to define a threshold of normality, and for what concerns HE4 levels, the menstrual cycle phase-dependent variability appears indicated in the interpretation of the results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490961     DOI: 10.1007/s13277-010-0049-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women.

Authors:  A B Erbağci; N Yilmaz; I Kutlar
Journal:  Dis Markers       Date:  1999-12       Impact factor: 3.434

2.  Correlation between peripheral CA-125 levels and ovarian activity.

Authors:  A Zweers; J De Boever; R Serreyn; D Vandekerckhove
Journal:  Fertil Steril       Date:  1990-09       Impact factor: 7.329

3.  Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle.

Authors:  A G Zeimet; E Müller-Holzner; C Marth; G Daxenbichler; O Dapunt
Journal:  Fertil Steril       Date:  1993-05       Impact factor: 7.329

4.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

5.  Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.

Authors:  D X Chen; P E Schwartz; X G Li; Z Yang
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

Review 6.  SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 7.  Biomarkers in early cancer drug development: limited utility.

Authors:  R H Glassman; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-02       Impact factor: 6.875

Review 8.  Serum and pleural fluid biomarkers for mesothelioma.

Authors:  Jenette Creaney; Bruce W S Robinson
Journal:  Curr Opin Pulm Med       Date:  2009-07       Impact factor: 3.155

Review 9.  CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F Ozols; William P McGuire; Franco M Muggia; Peter G Rose; David Spriggs; Deborah K Armstrong
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

10.  Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report.

Authors:  Hasan Kafali; Hülya Artuc; Nurettin Demir
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-09-10       Impact factor: 2.435

View more
  20 in total

1.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

2.  Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Authors:  Yan Zhang; Chunxia Qiao; Lian Li; Xuye Zhao; Yali Li
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

3.  Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer.

Authors:  Yuanzhu Jiang; Chao Wang; Baoyu Lv; Guoyuan Ma; Lei Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma.

Authors:  Keita Tokuishi; Shin-ichi Yamashita; Kazuyuki Ohbo; Katsunobu Kawahara
Journal:  Tumour Biol       Date:  2011-10-21

Review 5.  Recent advancements in fabrication of nanomaterial based biosensors for diagnosis of ovarian cancer: a comprehensive review.

Authors:  Rinky Sha; Sushmee Badhulika
Journal:  Mikrochim Acta       Date:  2020-02-19       Impact factor: 5.833

Review 6.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

7.  Falsely elevated human epididymis protein 4 results and Risk of Ovarian Malignancy Algorithm in polymorbid women after solid organ transplantation: A pilot and case-control study.

Authors:  Janka Franeková; Josef Cindr; Petra Lavríková; Jitka Komrsková; Peter Sečník; Věra Lánská; Antonín Jabor
Journal:  J Clin Lab Anal       Date:  2018-03-24       Impact factor: 2.352

8.  HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.

Authors:  Rafael Molina; Jose M Escudero; Jose M Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa
Journal:  Tumour Biol       Date:  2011-08-24

9.  Prognostic significance of HE4 expression in pulmonary adenocarcinoma.

Authors:  Shin-Ichi Yamashita; Keita Tokuishi; Takafumi Hashimoto; Toshihiko Moroga; Mirei Kamei; Kiyoshi Ono; Michiyo Miyawaki; Shinsuke Takeno; Masao Chujo; Satoshi Yamamoto; Katsunobu Kawahara
Journal:  Tumour Biol       Date:  2010-10-15

10.  Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression.

Authors:  Shin-ichi Yamashita; Keita Tokuishi; Toshihiko Moroga; Satoshi Yamamoto; Kazuyuki Ohbo; So Miyahara; Yasuhiro Yoshida; Jun Yanagisawa; Daisuke Hamatake; Masafumi Hiratsuka; Yasuteru Yoshinaga; Takeshi Shiraishi; Akinori Iwasaki; Katsunobu Kawahara
Journal:  Tumour Biol       Date:  2012-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.